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Background: Reports of patients with polymyxin-only susceptible gram-negative nosocomial
pneumonia treated with inhaled, but without concurrent intravenous, colistin are rare.
Methods: Patients admitted in a tertiary 450-bed tertiary care centre during the period 05/01/
2005e05/31/2007 and receiving colistin through nebulization, but not systemically, were
included in this retrospective case series.
Results: Five patients (three with ventilator-associated pneumonia and two with nosocomial
pneumonia) received colistin through nebulization without concomitant intravenous colistin.
The isolated pathogens were Acinetobacter baumannii (three cases), Pseudomonas aeruginosa
(one case) and the combination of Klebsiella pneumoniae, A. baumannii and P. aeruginosa
(one case). They were susceptible only to colistin (three cases) or to colistin and gentamicin
(two cases). Intravenous antimicrobial agents given concurrently were piperacillin/tazobac-
tam, meropenem, ceftriaxone and ciprofloxacin; isolated pathogens were resistant to these
agents. Four (80%) out of the five patients were cured, survived and were discharged. One
patient died. No colistin-related adverse event was observed.
Conclusions: The experience from this case series and other relevant recent reports suggest
that treatment of pneumonia due to polymyxin-only susceptible gram-negative bacilli with
inhaled colistin (without concurrent systemic administration) deserves further careful investi-
gation.
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708 M.E. Falagas et al.Introduction delivered via the Siemens Servo Ventilator 300 (Siemens-Treatment of patients with nosocomial pneumonia due to
multidrug-resistant (MDR) gram-negative bacteria is a chal-
lenging issue; in such cases, administration of colistin has
been advocated.1e3 Others and our research group have
examined the effectiveness and safety of intravenous
colistin given either alone4e7 or combined with inhaled
colistin8e10 for the treatment of such patients.
Administration of inhaled antibiotics (including colistin)
as an adjunctive to intravenous antimicrobials for the
prevention and treatment of nosocomial pneumonia, albeit
not generally accepted, has been supported on the basis of
comprehensive systematic reviews.11e13 In addition, the
relevant guidelines by the American Thoracic Society and
the Infectious Diseases Society of America note that
‘‘aerosolized antibiotics may be considered as adjunctive
therapy in patients with MDR gram-negatives who are not
responding to systemic therapy’’.14
On the other hand, administration of inhaled anti-infec-
tive agents without concurrent intravenous antimicrobials is
primarily indicated for cystic fibrosis patients with Pseudo-
monas aeruginosa infection,15 for prophylaxis (pentamidine)
against Pneumocystis jirovecii pneumonia for patients with
human immunodeficiency virus intolerant to oral agents, and
for patients with respiratory syncytial virus infection (riba-
virin).16 With regard to colistin, administration of inhaled
colistin without its concurrent intravenous administration
for nosocomial pneumonia has been reported, although very
rarely, in the literature.10,17,18 The relevant evidence has
been very recently accumulated and critically appraised.19
In clinical practice, physicians not rarely face condi-
tions, which discourage the systemic administration of
colistin (i.e. due to systemic toxicity), while the implicated
pathogen is a polymyxin-only susceptible one. An inter-
esting question is, thereby, arisen: might monotherapy with
inhaled colistin be an option in such ‘‘desperate’’ cases?
Herein, we present our experience with patients with MDR
gram-negative nosocomial pneumonia treated with inhaled
(without concurrent intravenous) colistin.
Methods
Study design and data collection
The present retrospective study was carried out at a 450-bed
tertiary care centre and was approved by the institutional
reviewboardof thehospital.All patientswho receivedcolistin
for more than 72 h for treatment of MDR gram-negative
infections from 05/01/2005 to 05/31/2007 were located from
the pharmacy electronic database and their medical records
were reviewed. Only patients receiving colistin through
nebulization, but not systemically, were included. Demo-
graphic, clinical, laboratory and radiological data for these
patients were recorded, as previously described.10Administration of inhaled colistin
In patients under mechanical ventilation (MV), 1 million IU
colistin was diluted in 2 mL sterile normal saline 0.9% andElema AB, Solna, Sweden). In spontaneously breathing
patients, 1 million IU colistin was diluted in 4 mL normal
saline and nebulized with 8 L/min oxygen flow.
Microbiological testing
An automated broth microdilution method (Vitek 2, bio-
Merieux, Hazelwood,MO, USA)was used for routine laboratory
susceptibility testing to commonly used antibiotics9; namely,
penicillins (piperacillin, piperacillin/tazobactam, ticarcillin,
ticarcillin/clavulanate ampicillin, and amoxicillin/clav-
ulanate), cephalosporins (cefaclor, cefepime, cefotaxime,
cefoxitin, ceftazidime, cefuroxime-axetil and sodium, cepha-
lothin, cefpirome, cefpodoxime), carbapenems (imipenem,
meropenem), monobactams (azactam), quinolones (cipro-
floxacin, norfloxacin, ofloxacin, pefloxacin), aminoglycosides
(amikacin, gentamicin, netilmicin, tobramycin, isepamicin),
and colistin. Susceptibility to colistin was determined by the
use of the colistin Etest strip (AB Biodisk, Solna, Sweden). Test
resultswere interpretedas showing susceptibility ofabacterial
isolate to colistin when the respective minimum inhibitory
concentration was 2 mg/mL.
Definitions
Pneumonia
Diagnosis of pneumonia was based on radiological (new or
progressive and persistent infiltrate), clinical (fever, purulent
respiratory secretions) and laboratory findings (abnormal
white blood cell count and gas exchange). All patients should
have microbiologically documented pneumonia based on
quantitative cultures of bronchial secretions.9,10
Nosocomial pneumoniaeventilator-associated
pneumonia (VAP)
Pneumonia occurring at least 48 h after hospital admission
or after the initiation of MV was considered nosocomial or
VAP, respectively.
MDR
Resistant to all but two antipseudomonal classes of anti-
microbial agents (namely antipseudomonal penicillins,
cephalosporins, carbapenems, monobactams, quinolones,
aminoglycosides, and polymyxins).
Polymyxin-only susceptible
Resistant to all antipseudomonal agents except colistin.
Cure/improvement
Defervescence, resolution or partial resolution of
presenting symptoms and signs of pneumonia, decrease
or disappearance of presenting findings on chest x-ray, and
improvement or normalization in arterial blood gases,
white blood cell count and C-reactive protein.
Results
Patient population
During the study period, in six patients colistin was given
through nebulization only (not systemically) for the
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six patients suffered from pneumonia due to P. aerugi-
nosa, which was susceptible to colistin and meropenem;
this patient was managed with inhaled colistin and
intravenous meropenem and, for this reason, was
excluded from this case series. The characteristics and
outcome data of the five included patients are depicted in
Table 1.
Four males and one female were included. The reason
of hospital admission was trauma (craniocerebral
lesions) in three and medical (one patient with acute
myocardial infarction and another with urinary tract and
soft tissue infection) in two of them. Three patients
developed VAP, one patient nosocomial pneumonia
treated in a ward, while the remaining patient suffered
from nosocomial pneumonia requiring ICU admission.
Thus, four of the five subjects of this case series were
admitted in the ICU; mean Acute Physiology and Chronic
Health Evaluation (APACHE) II score at ICU admission was
17.5.
Implicated pathogens and susceptibility
In three patients (# 2, 4, 5 of Table 1), the causative
pathogen was Acinetobacter baumannii. According to the
performance standards for antimicrobial susceptibility
testing developed by the Clinical and Laboratory Standards
Institute (CLSI),20 A. baumannii was polymyxin-only
susceptible in one patient (# 2) and MDR (susceptible only
to colistin and gentamicin) in the other two patients (# 4,
5). The gentamicin minimum inhibitory concentration of
the isolated pathogens in the latter patients (# 4, 5) was
4 mg/mL; a value indicating susceptibility to gentamicin
according to the CLSI.20 From another patient (# 3),
a polymyxin-only susceptible P. aeruginosa was isolated.
Finally, from the remaining patient (# 1) of this case series,
P. aeruginosa, A. baumannii and Klebsiella pneumoniae, all
susceptible only to colistin, were isolated.
Administration of inhaled colistin
Daily dosage of inhaled colistin was 1 million IU every 8 h
and 500,000 IU every 6 h in four and one patient, respec-
tively. It was administered for 6e11 days. No patient
received intravenous colistin. Intravenous antimicrobial
agents given concurrently were piperacillin/tazobactam,
meropenem, ceftriaxone and ciprofloxacin; isolated path-
ogens were resistant to these agents. One patient with VAP
due to A. baumannii, which was susceptible to colistin and
gentamicin, received gentamicin intravenously.
Outcome
Four (80%) (patients # 1, 3, 4, 5) out of the five patients of
this case series survived. Two (# 3, 5) out of these four
patients were discharged from the hospital; the remaining
two survivors (# 1, 4) were discharged from the ICU and
transferred to another hospital. Cure or improvement of
the gram-negative pneumonia episode was achieved in
three and one patient, respectively (clinical success: 4/5,80%). One patient (# 2) died. This patient was admitted in
the ICU due to severe acute myocardial infarction requiring
implementation of intra-aortic balloon pump. After 27 days
of ICU stay and MV, this patient developed VAP due to
polymyxin-only susceptible A. baumannii. He died 11 days
after this VAP episode onset due to cardiogenic shock.
Follow-up cultures were not available for all but one
patient. In this patient (# 4), A. baumannii persisted in
bronchial secretions obtained 5 days after the initiation of
colistin administration. This patient was cured and dis-
charged; no repeated cultures were obtained.
Tolerance and safety of inhaled colistin
No patient experienced adverse events from the respiratory
system related to the inhalation of colistin, such as bron-
choconstriction, chest tightness or apnoea. Serumcreatinine
level of the five patients was not deteriorated (Table 1).
Discussion
We present a case series of five patients with MDR gram-
negative nosocomial pneumonia treated with inhaled (but
not intravenous) colistin. The implicated pathogens (mainly
A. baumannii and P. aeruginosa) were polymyxin-only
susceptible in three cases and susceptible to colistin and to
gentamicin in the remaining two cases (one of these two
patients did not receive gentamicin). All but one patient
survived and were discharged.
It may be interesting to clarify the reasons why these
five patients were not given colistin intravenously. In
detail, three of them (namely patients # 1, 4, 5) suffered
from recent craniocerebral lesions. Concerns regarding
neurotoxicity associated with systematic administration of
colistin discouraged physicians from prescribing it in such
potentially vulnerable patients.21,22 This may be also the
case for another patient (patient # 3) with a history of post-
traumatic tetraplegia and agrypnodal coma. For this
particular patient, the fact that pneumonia due to poly-
myxin-only susceptible P. aeruginosa was not severe (ICU
admission was not required) may also contribute to the
explanation why care providers considered inhaled colistin
as adequate for his management. For the remaining patient
(patient # 2) of our case series, his impaired renal function,
as indicated by the elevated serum creatinine level
(1.7 mg/dL), presumably discouraged caregivers from
administering intravenous colistin for his episode of VAP
due to polymyxin-only susceptible A. baumannii.
Pharmacokinetics/pharmacodynamics of colistin is
currently the subject of intense research.23 With respect to
inhalation therapy, it seems reasonable that the exact
delivery of a medication directly to the suffering lung tissue
may be beneficial. Indeed, pharmacokinetic studies have
shown that a single inhalation of 2 million IU of colistin leads
to high sputum concentrations of the drug even 12 h after the
administration.24 Colistin exerts its action through
a concentration dependant bactericidal mechanism. It
displays the cations of Caþ2 and Mgþ2 that stabilize the outer
membrane of gram-negative bacteria and, thus, lead to
outer membrane disruption and cell death.25 Also, colistin
reduces the production of endotoxins and cytokines. Finally,
Table 1 Characteristics and outcome data of the five patients receiving inhaled (but not intravenous) colistin for the treatment of multidrug-resistant nosocomial
pneumonia.
Data Patient
1 2 3 4 5
Characteristics
Sex/age (years) Female/80 Male/75 Male/26 Male/18 Male/27
Medical history Cardiac valvuloplasty Coronary disease;
arterial hypertension;
diabetes mellitus
Post-traumatic tetraplegia;
coma agrypnodal;
tracheostomy
None None
Type/reason of
hospital admission
Trauma/craniocerebral
lesions; subdural hematoma;
femoral fracturea
Medical/acute
myocardial infarction;
acute pulmonary edema
Medical/UTI; SSTI Trauma/multitrauma
patient due to car
accident; craniocerebral
lesions
Trauma/multitrauma
patient;
craniocerebral lesions
Diagnosis of discharge Craniocerebral lesions;
nosocomial pneumonia
Acute myocardial
infarction; cardiogenic
shock; VAP
UTI; SSTI; nosocomial
pneumonia
Craniocerebral lesions;
VAP
Craniocerebral lesions;
multiple rib fractures;
scapula fracture; VAP
APACHE II score at
ICU admission
27 20 Was not admitted
in ICU
12 11
Episode of pneumonia
Duration of MV before
pneumonia onset (days)
0 27b Did not receive MV 8 8
Duration of hospital
and ICU stay
before pneumonia
onset (days)
Hospital: NA; ICU: 0 Hospital: 27; ICU: 27 Hospital: 3 Hospital: 8; ICU: 8 Hospital: 8; ICU: 8
Site of infection Nosocomial pneumonia
requiring MV and ICU
admission
VAP Nosocomial pneumonia
(ward); UTI; SSTI
VAP VAP
Isolated gram-negative
pathogen(s) (culture)
Pseudomonas aeruginosa
(bronchial secretions,
central venous catheter tip);
Acinetobacter baumannii
(bronchial secretions, central
venous catheter tip);
Klebsiella pneumoniae
(bronchial secretions)
A. baumannii
(bronchial
secretions)
P. aeruginosa
(bronchial secretions);
K. pneumoniae (urine);
Proteus mirabilis
(urine, soft tissue abscess)
A. baumannii (bronchial
secretions)
A. baumannii
(bronchial secretions)
Susceptibility of the
gram-negative
pathogen(s) isolated
from respiratory
specimens
POS POS POS MDR (susceptible to
colistin and gentamicin)
MDR
(susceptible to
colistin and gentamicin)
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Duration/dosage of
inhaled colistin
6 days/1 million IU q8h 6 days/1
million IU q8hc
7 days/1 million IU q8h 1 days/0.5 million
q6h
6 days/1 million IU q8h
Administration of
intravenous colistin
No No No o No
Duration/dosage of
concurrent intravenous
antimicrobial treatment
Piperacillin/tazobactam:
7 days/4.5gr q6h
Meropenem: 5 days/1gr
q12h; ceftriaxone:
8 days/2gr q24h
Piperacillin/tazobactam: 11
days/4.5gr q8h; ciprofloxacin:
5 days/400 mg q12h
eropenem:
3 days/1gr q8h
Gentamicin: 7 days/
80 mg q8h; piperacillin/
tazobactam: 8 days/
4.5gr q8h
Outcome
Outcome of patient ICU discharge Death Hospital discharge U discharge ICU discharge
Outcome of infection Improvement Deterioration Cure ure Cure
Duration of MV after
pneumonia onset (days)
3 11 Did not receive MV 3
Duration of
ICU/hospital stay after
pneumonia onset (days)
ICU: 11 ICU: 11 Hospital: 10 U: 24 ICU: 6
Safety
Serum creatinine
value (mg/dL) at the first
day of colistin
inhalation/at the end of colistin
inhalation (change)
0.5/0.5 (0) 1.7/1.3 (0.4) 0.6/0.5 (0.1) .5/0.5 (0) 0.6/0.6 (0)
Adverse events
from respiratory systemd
None None None one None
Abbreviations: MV: mechanical ventilation, ICU: intensive care unit, POS: polymyxin-only susceptible, VAP: ventilator-associated pn monia, NA: not available, APACHE: Acute Physiology
and Chronic Health Evaluation.
a This patient was referred from another hospital due to nosocomial pneumonia requiring intensive care unit admission.
b Until the episode of ventilator-associated pneumonia due to polymyxin-only susceptible A. baumannii.
c He also received inhaled colistin 0.5e1 million IU q8h for 14 days before the episode of ventilator-associated pneumonia d to
polymyxin-only susceptible A. baumannii.
d Namely bronchoconstriction, chest tightness, apnoea.
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712 M.E. Falagas et al.inhaled colistin could demonstrate a unique action against
certain pathogen populations’ growth inside biofilms.26
The retrospective design, sample number of patients,
and the absence of a control group are limitations of this
case series. In addition, we should note that the patients of
our report received concurrently intravenous antibiotics;
however, the responsible pathogens were not susceptible
to intravenous antibiotics (except from patient # 5). With
regard to patient # 5 (who received both inhaled colistin
and intravenous gentamicin for VAP due to A. baumannii
susceptible to colistin and gentamicin), one might call into
question our decision to include him in the present case
series. This preservation seems logical. However, there is
evidence that aminoglycosides do not penetrate
adequately into the lung27 and, therefore, monotherapy of
nosocomial pneumonia with aminoglycosides is not recom-
mended.14 Thus, it seems plausible that administration of
inhaled colistin rather than intravenous gentamicin was
responsible for the cure of this patient. Furthermore, one
might criticize us for establishing the diagnosis of nosoco-
mial pneumonia and VAP on non-invasive (i.e. cultures from
bronchial secretions) rather than invasive (i.e. bronchos-
copy) diagnostic methods. However, on the basis of
a recent randomized controlled trial, non-invasive and
invasive diagnostic strategies for VAP did not differ with
regard to clinical outcomes (including mortality) and the
overall use of antibiotics.28 Besides, according to the
relevant guidelines by the American Thoracic Society,
quantitative cultures of non-bronchoscopic bronchial
secretions can reliably guide antibiotic therapy decisions
when bronchoscopic sampling is not available.14 Finally,
one could assume that the organisms treated may not have
been the etiology for the nosocomial and ventilator-asso-
ciated pneumonia in the patients of our report.
In conclusion, we report on five patients with MDR gram-
negative nosocomial pneumonia (including VAP) due to
polymyxin-only susceptible or MDR gram-negative bacteria
treated with inhaled (without intravenous) colistin. The
favourable outcome of pneumonia in four out of the five
reported cases seems to suggest that this intervention may
deserve further investigation in patients with pneumonia
due to polymyxin-only susceptible bacteria, especially in
patients for whom the possible toxicity of systemic
administration of polymyxins is a consideration.
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